What's behind Hims & Hers Health's latest stock pullback?

Traders Union
All News
Financial News
Hims & hers drops 4.12% today

Highlights

Bank of America Securities reiterated its Neutral rating on Hims & Hers Health while raising the price target to $37, signaling modest confidence in the company's outlook.
Despite an $8.35 billion market cap and direct-to-consumer healthcare offerings, the stock remains under broader selling pressure in the sector.
Technical signals are mixed; while the stock holds above key support near $33.34 and projects a five-day range of $31.56–$36.43, intraday volatility persists with buyers dominant but short-term consolidation likely.

Raised target and neutral stance as selling persists amid sector flows

A 'Neutral' rating was maintained on Hims & Hers Health by Bank of America Securities, which also raised the price target to $37 as of October 4, 2023. The telehealth company provides direct-to-consumer medical treatment options in specialties such as erectile dysfunction, hair loss, skincare, mental health, and weight loss. The company operates within the healthcare sector with a market capitalization of roughly $8.35 billion, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees the sustained pressure on Hims & Hers Health as a warning despite technical strength above key averages. He notes that the mix of bullish and bearish signals, especially the Hull Moving Average's sell indication and longer-term MA alignment, create uncertainty for bulls. He highlights that although Bank of America's higher target offers some support, price action has not followed through. The split momentum signals and broad market weakness cast doubt over the recent optimism. As Kharitonov puts it, "Beneath the surface, risk remains elevated — consolidation may not hold if selling pressure persists."

Viktoras Karapetjanc, expert at Traders Union, notes that Hims & Hers Health maintains a strong technical structure, staying above all major moving averages. He highlights the constructive market view, especially with Bank of America raising its price target and endorsing the company’s growth in telehealth. Karapetjanc is confident that healthy sector momentum and supportive forecasts can drive further upside. He asserts, "The bullish structure remains intact, and Hims & Hers Health offers multiple setups for continued growth toward the resistance zone."

Bullish average alignment diverges from mixed momentum signals

Hims & Hers Health is trading above its 20-day, 50-day, and 200-day moving averages—at $33.34, $28.94, and $32.31 respectively—indicating bullish alignment across all timeframes. The near-term resistance is set at $34.18, with the closest support at $33.34 and additional underlying support from the Ichimoku Kijun at $32.24. Despite ongoing price stability above all key averages, the longer-term MA-50 versus MA-200 alignment points to a bearish backdrop. Momentum signals are mixed, as MACD and ADX remain in buy territory and the RSI at 59.56 supports a bullish stance, while the Stochastic RSI at 0 signals oversold conditions. The CCI at 66.78 and Bull/Bear Power at 1.51 both favor bulls, though BBP levels indicate some overbought risk. The Awesome Oscillator is neutral, and the Hull Moving Average gives a sell signal, contributing to a divergence amongst short-term and momentum indicators.

Earlier, analysts noted that Hims & Hers Health was under persistent selling pressure with an increased probability of further downside, highlighting market caution despite ongoing strategic initiatives. The current technical stability above all major moving averages presents a more neutral-to-positive setup, but traders should watch for a decisive move through resistance or support as a trigger for the next directional shift.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.